ArticleJournal of mass spectrometry : JMS2026
Validation of a MALDI Intact Cell Mass Spectrometry Workflow for Routine Application in Monitoring Industrial E. coli Fermentations.
Article in Journal of mass spectrometry : JMS, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Today, matrix-assisted laser desorption/ionization-intact cell mass spectrometry (MALDI-ICMS) is used in clinical environments for rapid pathogen identification, referred to as MALDI biotyping. This method relies on the generation of characteristic mass spectrometric profiles of intact microorganisms. Single-celled organisms are often used for pharmaceutical production, while this allows for the production of complex products, close monitoring and control of these processes is essential. In this study, we propose the use of MALDI-ICMS as a potential at-line approach for fast monitoring of the progress of a biotechnologically relevant fermentation process employing E. coli as a host. We demonstrate the reproducibility of the method, thereby indicating its potential to predict the progress of antibody fragment production in E. coli in an industrial setting. We evaluated various aspects of sample preparation, including the choice of matrix and solvent concentration, sample loading, and sample-to-matrix ratios. Our workflow allowed monitoring of over 100 signals across a 32-h span of E. coli fermentation. To control instrumental variability, we performed eight technical replicates and achieved excellent repeatability, with 9% median relative standard deviation of peak intensities. Principal component analysis revealed strong time-related differences of the mass spectra, allowing to differentiate the data based on fermentation phases. Furthermore, to assess direct monitoring of product expression, we adapted acquisition parameters to enable product detection via MALDI-ICMS. The presented MALDI-ICMS workflow allowed reliable monitoring of cellular changes during fermentation, thereby expanding the applications of MALDI-ICMS to process analytical technologies (PAT).
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.